Tags Posts tagged with "cbis"

cbis

1 11859

How Have Marijuana Stocks Performed Post Trump?

Here we are, the official inauguration day of our 45th President of the United States of America, Donald Trump. A lot has been said about him over the last few years during the election race but what many may not have expected was a clear “Trump Bump” for marijuana stocks.

As we’ve said in the past, a lot of marijuana stocks are event driven. Going all the way back to 2014 and during the years to follow, catalysts in the cannabis market can be tied to actual events in many cases. For this most recent jump in marijuana stock prices, we see that an election year and a not so conservative President may be the event to thank for this.

In this article we’ll briefly explore some of the most active and most bullish marijuana stocks in the market to give a clear example of “where we’ve been” and what we might be able to look forward to as to “where we’re going”.

OWC Pharmaceutical Research Corp. (OWCP) 3,512%

This company has been building steam since October and just recently went into overdrive to all time highs. Through its subsidiary, One World Cannabis, the Israeli-based company develops cannabinoid-based therapies that target different medical conditions. This was another cannabis biotech company that saw the impact of Trump coming into office instead of Clinton (who was very bearish on biotech).

In late October just before the elections, OWCP saw its first noticeable move from under $0.03 and initially ran to highs of $0.215. Following the consolidation period heading into the end of the year (as most marijuana stocks saw), January opened the door for this stock to run as high as $0.95

OWCP_Marijuana_Stocks

 

Rocky Mountain High Brands (RMHB)
271%

We’ve reported on this company and followed it for a few years. Even before when it was “Totally Hemp Crazy (THCZ)” this stock saw one of the biggest breakouts that we’ve every witnessed. It went from sub penny to highs of 0.32 within weeks. Now it appears that chart has demonstrated a similar Trump Bump that many of the other marijuana stocks have also seen.

In early October, volume began to build, RMHB ran from $0.031 to highs of $0.07. After consolidating back to 0.03-0.04, RMHB has now seen its 2017 rally trigger and has now managed to run past $0.11. Rocky Mountain is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots, as well as a Relaxation Brownie.

Marijuana Stock

Ubiquitech Software Corp. (UBQU)
304%

UBQU follows a similar trend where even though it hasn’t broken above its year end highs, the stock has seen a reversal that started at the beginning of 2017. A lot of questions were raised regarding a previously announced name change and recently the company gave clear guidance on this for 2017 that has brought attention back to the stock from market bulls. Its final name change will be Endo BioSciences Inc., and HempLife Today™ will continue to be the main subsidiary of the company.

HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; its popular CBD Tinctures, Oils, GelCaps, CBD Powder, Skin Salve, Wax Crumble, and e-liquid.

marijuana stocks

mCig, Inc. (MCIG)
1,265%

A company that we’ve kept up with for the better part of the last year, MCIG became another clear example of what marijuana stocks have started to look like after Donald Trump was elected President. The company has been making many key strides over the last few months including posting some of its best numbers in history.

This includes MCIG currently holding over $10 million in order/contract backlog (as of their last PR in December). In similar fashion to OWCP, shares of MCIG saw a bump in late October when the stock moved from under $0.04 to as high as $0.218. After consolidating in early December, MCIG manage to rally strong heading into the end of the year and recently hit highs of $0.505.

cannabis stocks

Axim Biotechnologies, Inc. (AXIM)
3,941%

Another company that we’ve been following very closely, this has been one of the biggest runners of the year amid heavy volatility. Another cannabis biotech, the company focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. MJNA is also an investor in AXIM.

In late October the stock was trading just under $0.50 moved to a high of $10 before consolidating to levels between $7.50-$8. Wouldn’t you know it, heading into the beginning of 2017 the stock broke the sideways trend and moved to highs of $19.80.

cannabis stock

Vitality Biopharma (VBIO)
361%

A company that many of us are familiar with, this cannabis biotech had a smaller run a few weeks before we started picking up coverage. In early October, the stock moved up from around $0.92 to highs of $1.84. After pulling back to lows in December, we began looking at this company at $0.98 and watched as it ran to highs of $4.24. The company is a cannabis biotech focusing on treating disease through its prodrug utilizing cannabinoids for the treatment of serious neurological and inflammatory disorders.

marijuana

Cannabis Science (CBIS)
469%

The company specializes in the development of cannabinoid-based medications and recently announced a collaborative research agreement with Dana Farber/Harvard Cancer Center. Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

From October 3 to October 19 CBIS jumped from $0.0169 to as high as $0.077. After pulling in during December, the stock kicked off the new year with a big bull run all the way to highs of $0.0961 for the year so far.

cannabis

Hemp Inc. (HEMP)
103%

One of the most vocal companies on Hemp production in the US, Hemp Inc. They’ve continued to push for a ubiquitous acceptance for all uses of the hemp plant for years now and have targeted North Carolina to grow over 3,000 acres of hemp.

“We are proud to collaborate with other American industrial hemp farmers as we now become part of the modern industrial hemp farming movement. This is a turning point for America and it’s a turning point for Hemp, Inc. Hemp, Inc. has the infrastructure in place to process millions of pounds of hemp fibers and stalks a year, on a commercial level. Our 70,000 square foot industrial hemp processing facility, on over 9 acres in Spring Hope, North Carolina, is the only one of this magnitude in North America. The industrial hemp crop is part of history in the making and it is something that will prove to be lucrative not only for the farmers in North Carolina but for Hemp, Inc. as well,” said CEO Bruce Perlowin in a recent PR.

HEMP saw a bump in volume early in October, the stock ran from $0.0276 to $0.056 before consolidating in late November/December, and has once again begun to aggressively climb back from that price channel.

hemp

Cannabis Sativa, Inc. (CBDS)
195%

With multiple subsidiaries, this company has products ranging from hemp oils & capsules to cannabidiol infused bottled water and even its own patented cannabis plan named Ecuadorian Sativa (Patent PP27,475). Back in late September the stock was trading around $2.80 per share before it jumped up to highs of $8.25. After consolidating for weeks leading up to the new year, CBDS has once again followed suit of many marijuana stocks having now climbed back above $8.

CBD

OH CANADA!

This leads us to our “neighbors up north” because we haven’t just seen a boom from US marijuana stocks alone. The trend has echoed into Canada with some of the most anticipated IPOs so far this year

Emblem Corp. (TSXVENTURE:EMC)(OTCQB:EMMBF)
55%

Emblem Corp, a Licensed Cultivator out of Paris Ontario is one of the most watched and anticipated offerings that has come out of Canada in the last few months. Beyond the fact that they are already growing cannabis and revenue producing investors have taken note of one of their founders and current President, a gentleman by the name of John Stewart.

No, not John Stewart from the Daily Show even though that would be awesome, John Stewart former CEO of Purdue Pharma one of the largest private biotech companies in the world and creators of OxyContin. We see the potential long term to create a cultivator/Biotech hybrid in which case Emblem could be the Next GW Pharma of Canada.

Marijuana IPO

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CNSX: IN)
326%

This company has been following the same pattern as many of the other cannabis biotechs but also comes with what looks to be a stock promotion behind it. The company recently appointed Jeff Charpentier, CPA, CA as InMed’s Chief Financial Officer & Corporate Secretary as well as Martin Bott to its Board of Directors; Bott has worked at Eli Lilly & Company since 1988 and held a variety of roles in the U.S., Switzerland, Germany, and the UK.

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. IMLFF saw a rise in price early in October (shocker right?), a period of consolidation leading up to the new year, and since that ball dropped, the stock has been on the run moving from $0.10 in October to highs of $0.4261 just a few days ago.

Marijuana Stocks

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF)
179%

The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada.

They just announced that the company has officially surpassed 12,000 registered patients within the first 12 months of product sales in Canada. They also announced that they had signed a Joint Venture Research Agreement with Radient Technologies Inc. (“RTI”). The first phase of this venture will include screening experiments of extraction conditions, while phase two includes larger scale experiments related to extraction throughput and optimal extraction conditions. Aurora’s scientists and the RTI team will commence tests January 16, 2017, and the first phase is expected to be completed within approximately six weeks, so something to keep an eye on here in our opinion.

Likewise with the other stocks, the market activity has followed suit even though Aurora has differed by not breaking a new high this year as compared to the high it made in November. But the new uptrend on the chart could be a key indicator for future potential. Since October (at $1.06), shares of ACBFF has seen two and possibly three clear runs; One that saw highs of $1.89 before consolidating, another that saw highs of $2.96 before consolidating, and possibly a new uptrend forming now in January.

Buy marijuana stocks

These are just a few marijuana stocks that have demonstrated a near identical move in the market both leading into the election and leading up to the inauguration. We’ve said it before and most likely will say it again: Marijuana Stocks can very much be event driven so something to keep in the back of your head as we watch 2017 unfold. As investors become more informed on the industry itself, we’ll keep our had on the pulse to find the real story behind some of the biggest marijuana stock moves in the market today.

 

 

 

 

 


 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. MAPH owns 2 million common restricted shares of mCig Inc. MAPH owns 10 million common restricted shares of Hemp Inc. An affiliate of MAPH owns 70,850 common restricted shares of Emblem Corp. We may buy or sell additional shares of any stocks mentioned, in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information

0 2515

Monday (3/14), one of the cannabis industry leaders, GW Pharma (GWPH) announced positive results from its first Phase 3 study of Epidiolex in the treatment of Dravet syndrome. Epidiolex already has orphan drug designation and Fast Track Designation from the FDA for this rare form of epilepsy. Currently there are no treatments approved in the U.S. The Active substance in Epidiolex, cannabidiol or CBD, has been the source of conversation and controversy for years.

Many doctors have even condemned it as a false therapy for things like cancer and, yes, epilepsy. But with the advent of strains like Charlotte’s Web, which have shown to drastically curb the affects of epilepsy, these Phase 3 results may confirm much of what many in the health community has already confirmed, which is that CBD’s can be a strong reactive therapy for debilitating diseases like this.

These findings could mean big things for the marijuana industry, as the ripple effect seems to have already begun. GW Pharma stock sprinted 120% to 84.71 in the stock market Monday, hitting a three-month high above 91, intra-day. The news also jump started other cannabis-related stocks like Insys Therapeutics (INSY), which rose 11% to 18.89, and the recently IPO’d Zynerba Pharmaceuticals (ZYNE), which increased to a six month high of $21.08; up 150%.

Like GW Pharma, Insys is also testing a CBD product in Dravet syndrome, and similarly has been granted an orphan-drug designation from the FDA. Zynerba is developing a form of CBD that can be applied through the skin. In a recent PR, ZYNE reported that in the first half of 2016, the Company expects to report final results from its ongoing Phase 1 single rising dose clinical trial, including results from 12 patients with epilepsy.

Other CBD Related Stocks Seeing More Attention From GW’s Findings:

FBEC Worldwide, Inc. (FBEC)

Originally focused on providing hemp based energy drinks, FBEC has also spread its reach into the quality CBD marketplace through its distribution of Ma Brand CBD. Late last year the company signed a Joint Venture agreement with CBD Globe Distributors Ltd. in which FBEC will own 50.1% of the newly formed Joint Venture LLC and receive 50% of the net profit from its operations. According to CBD Globe, it has invested over $200,000 in production and development of the Ma brand itself and already has 10,000 units packaged and ready for sale. The CBD vaping product has a highly refined CBD oil made from hemp, grown in the United States.

Top UFC contender, Anthony “Rumble” Johnson, has endorsed the company’s hemp energy shot product. Furthermore, its most recent announcements have dealt heavily with revamping its share structure and curbing potential sources of future dilution. FBEC shares rose just over 25% from Monday’s open and closed at the high of day.

GreenGro Technologies, Inc. (GRNH)

GRNH also acquired Greensticks, Inc.; a patent pending technology for an electronic vaporizer for Cannbidiol (CBD). Branded as a new way to medicate, Greensticks is a battery powered electronic vaporizer designed to look like an electronic cigarette. The cartridges are filled with 100% organic liquefied flowers and pharmaceutical grade glycol as found in asthma inhalers.

GRNH recently announced record-breaking 242.94% year-over-year sales growth through the first quarter of 2016. According to the company, this timely growth came as a result of new customers along with renewals and the ongoing expansion of the company’s product lines. Additionally, sales increased by 209.57% from the fourth quarter of 2015 to the first quarter of 2016. Along with many other marijuana stocks, GRNH shares increased by nearly 60% from open to high and closed the Monday session at its HOD of $0.349 on more than 5 times it’s average 30-day volume.

Medical Marijuana Inc. (MJNA)

This marijuana stock saw very heavy volume on Monday with price increasing by a modest 7% from its previous close, Friday. The company announced at the beginning of March that its portfolio investment company, KannaLife Sciences, Inc. has received the necessary 2016 quota allotment from the U.S. DEA to import high-purity, pharmaceutical-grade cannabidiol into the U.S.

KannaLife is currently focused on the feasibility studies with Catalent Pharma to develop a cannabinoid-derived therapeutic agent for the treatment of two neurodegenerative diseases: Hepatic Encephalopathy and Chronic Traumatic Encephalopathy; forms of brain degradation in humans that can be due to things like head trauma.

Cannabis Science, Inc. (CBIS)

This stock saw an incredible day on Monday as well. The stock increased from an opening price of $0.01 to a high of $0.0194. The stock ended the day, closing up just under 50%. The company is continuing testing and providing limited rollouts for its own CBD-based treatment products in California. The company has taken a strong stance to increase shareholder value.

In recent press Cannabis Science’s CEO announced that he will be gifting his own shares to shareholders in lieu of previously announced dividends. That date of record for shareholders has been extended to March 31, 2016.

CV Sciences. (CANV)

The stock saw nearly 3 times its average 30-day volume on Monday fueled by excitement in the marijuana sector. Share prices rallied up more than 75%. In most of the recent press releases, the company has been focused on extinguishing the remainder of its convertible debt and as of early March, CANV management confirmed that 100% of the outstanding convertible promissory notes have been retired.

Following the acquisition of CanX and Canabine earlier this year, the company has taken a firm stance on efforts to develop synthetically-formulated CBD for use in drug development activities. In particular, they are looking to pursue approval of the FDA for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. Board Chairman James A. McNulty has been an active contributor to biotechnology and health care related companies, including BioDelivery Sciences International, Inc. (BDSI), Hedgepath Pharmaceuticals, Inc. (HPPI), Accentia Biopharmaceuticals, Inc., and Biovest International, Inc. He is also a former shareholder of CanX, which brings this full circle.

Conclusion

There are obviously many more marijuana stocks that could be mentioned here but it would seem that the CBD-centric companies like those mentioned, have begun to benefit from the latest ground breaking announcement that GW Pharma has just made with regard to a successful Phase 3 study. With such a late stage success, we think that the hemp, CBD and cannabis space will be a topic of major discussion in 2016.

 

 

Additional disclosure/disclaimer

An affiliate of MAPH Enterprises, LLC MarijuanaStocks.com | WolfofWeedStreet.com was paid an advertising fee of $60,000 cash & 60 Million Restricted Common shares by FBEC Worldwide Inc. (FBEC) for visual sponsorship of MarijuanaStocks.com | WolfofWeedStreet.com and for visual placement FBEC Worldwide Inc. (FBEC) within written materials. FOR A DURATION OF 5 YEARS BEGINNING JUNE 2015 ending JUNE 2020

0 1269

Form 10-Q/A for CANNABIS SCIENCE, INC.


24-Nov-2015

Quarterly Report

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThis section of this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like:
believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

Overview of the Company’s Business

Cannabis Science, Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical cannabis research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

CS-S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.

CS-TATI1 is in preclinical development with the indication for infectious disease. Consistent with data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.

In November 2013, Cannabis Science submitted patent application N2010968 in Europe entitled “Composition for the Treatment of Neurobehavioral Disorders.” The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with a strategic partner and related company, OmniCanna Health Solutions, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade product development.

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Some key phytocannabinoids are:

tetrahydrocannabinol (THC)

cannabidiol (CBD)

cannabigerol (CBG)

cannabichromene (CBC)

cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC.

Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire “seed to sale” process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions.

On March 30, 2009, the Company entered into an agreement with Cannex Therapeutics, LLC, (“Cannex”) a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The asset purchase agreement includes all of Cannex’s and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website www.phytiva.com. The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to Cannex, and K & D transferred 8,500,000 shares to Cannex and others. A Form 8-K reflecting this transaction was timely filed.

As part of the Agreement, on April 1, 2009, the Company appointed Mr. Kubby as President and CEO, Richard Cowan as Director and CFO, and Robert Melamede Ph.
D., as Director and Chief Science Officer. Each of them was also appointed as a director. All of the Company’s current directors then resigned. On April 7, 2010, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. Its shares now trade under the symbol CBIS.OB. A Form 8-K was timely filed, with a copy of the Asset Acquisition Agreement and Board Resolution ratifying the Agreement provided as exhibits thereto.

On April 7, 2009, the Company changed its name to Cannabis Science, Inc., reflecting its new business mission: Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.

On May 7, 2009, the Company common shares commenced trading under the new stock symbol OTC: CBIS.

The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10th and May 6th, 2013, respectively, to pursue business opportunities in Europe and worldwide.

There are minimal operating activities in the subsidiaries as of September 30, 2015. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MLS Lap B.V. and MJR B.V. until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT that would increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company has agreed to issue a total of twenty million (20,000,000) shares to the principals and shareholders of MGT over 12 months (see Form 8-K with the SEC on file no. 000-28911 August 8, 2014).
The August 6, 2014 offer to purchase an additional 30.1% equity in MGT is on hold until the litigation is resolved.

On May 7, 2015 the Company announced the acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including “Large Animal” such as horses, cattle, sheep and the like and “Small Animal” or “Pets” include cats, dogs, pet snakes and the like for medical and cosmetic products.

The Company is working on several business acquisition and development projects to increase business and revenue generation in 2014 and beyond, including but not limited to: product licensing and royalty agreements, private label hemp product line, consulting, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in 2014.

Liquidity

The Company has a working capital deficit of $5,016,417 as of September 30, 2015 compared to a working capital deficit of $3,788,922 for the year ended December 31, 2014. There are insufficient liquid assets to meet current liabilities or sustain operations through 2015 and beyond and the Company must raise additional capital to cover the working capital deficit. Management is working on plans to raise additional capital through private placements and lending facilities. The Company currently is relying on existing cash and loans from stockholders to meet its obligations and sustain operations.

The Company has promissory note payment commitments of $1,340,156 due to stockholders and currently in default. The Company is negotiating with the debtors to extend the notes payable.

Contractual Obligations

The Company has various commitments under consulting contracts, debt settlement, licensing agreements, laboratory services agreement, joint development, and joint venture agreement.

Capital Resources

On January 15, 2015, the Company sold 10,000,000 units at $0.25 per unit. Each unit is comprised of one share of common stock and one non-transferable warrant with each one warrant to purchase one share of the Company’s common stock at an exercise price of $0.50. The warrants shall expire 2 years from the date of issuance of the warrant certificate (collectively “Offered Units”). Gross proceeds of $250,000 were received by the Company under the offering on January 27, 2015.

The Company has additional capital resource requirements for personnel, supplies, laboratory and scientific equipment of approximately $1,250,000 over the next 12 months. These capital disbursements are dependent on management’s successful raising of capital through private placements and/or lending facilities.

The Company is not currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.

Results of Operations

For the nine months ended September 30, 2015 (“2015″) as compared to the prior year nine months ended September 30, 2014 (“2014″):

The Company had $4,150 in revenues for the 2015 compared to $1,031 for 2014.
This increase in revenue is due to acquisition of EquiPharm

Net loss on settlement of debt increased by $770,000 to $ 4,488,076 for the nine months ended September 30, 2015 compared to $2,116,500 for the nine months ended September 30, 2014. This increase is due to the higher share price of the Company’s stock and relative loss related to settling debt at a lower share price.

General and administrative expenses increased by $2,967,024 to $8,710,982 for the nine months ended September 30, 2015 compared to $4,845,803 for the nine months ended September 30, 2014. This increase is due to increased stock compensation expense pursuant to management consulting and bonus agreements.

The Company is working on several business development projects to generate revenues, including: signing a new license agreement with Apothecary Genetics Investments LLC that will generate increased license and royalty revenue, a hemp product line, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. The Company’s drug development with the pending joint venture with Unistraw is also ongoing through its laboratory services agreement with ImmunoClin Limited in London, UK. In addition, the Company signed an agreement with Equi-Pharma for the commercialization of pet products for distribution in California. Notwithstanding, there can be no assurance that these will be successful in generating revenues in 2015.

0 1073

Cannabis Science Highlights Additional Attendees at the Washington DC, African Union, CFA African Healthcare Infrastructure Forum and Brainstorm on February 6, 2015

Cannabis Science and Raymond C. Dabney Joins the Fight for a Better African Healthcare Infrastructure

COLORADO SPRINGS, Colo., Feb. 11, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, highlights additional attendees at the CFA African Healthcare Infrastructure Forum and Brainstorm held at the African Union, in Washington DC, on February 6, 2015.

As previously announced, Cannabis Science President & CEO, Raymond C. Dabney was appointed as the Vice Chair of the newly launched Constituency for Africa (CFA) Africa Healthcare Infrastructure Committee. ( www.cfa-network.org ) (https://www.facebook.com/pages/Constituency-for-Africa/347822291974589 )

The committee held its inaugural meeting on February 5, 2015 at the African Union Mission to discuss its charge from CFA President, Mr. Melvin Foote, and to approve a conceptual framework program of work. Building on the successful model by CFA of using Town Hall formats and commissioning lectures to highlight priorities, The Committee discussed to hold the Africa Healthcare Infrastructure Forum & Brainstorm Session on February 6 at the African Union Mission in terms of the expected outcome and to establish the five standing sub-committees on EDUCATION, AGRICULTURE, FOOD SECURITY, TECHNOLOGY & COMMUNICATION, LEADERSHIP, POLITICAL ENGAGEMENT & POLICY, and HEALTHCARE INFRASTRUCTURE to develop and sustain programs in these areas.

Mr. Dabney joined Dr. Roscoe M. Moore Jr. (retired US Assistant Surgeon General) who is Interim Chair of CFA and also Chair of the Africa Healthcare Infrastructure Committee, along with 13 others consisting of individuals with extensive experience working in or with Africa in the public and private sectors at the African Union for the African healthcare brainstorm session.

Among them is Dr. Julius Garvey, an accomplished board certified surgeon specializing in the diagnosis and treatment of cardiovascular disease, the son of the legendary pan-Africanist Marcus Garvey Jr., Dr. Sam Mbulaiteye, who is a senior investigator at the National Cancer Institute, and Prof. Allen Herman, an independent public health consultant who was the founding Dean of the National School of Public Health, Medical School of Southern Africa in South Africa.

The Africa Healthcare Infrastructure Forum & Brainstorm Session was held on February 6, 2015 at the African Union Mission in a historic event graced by a Keynote speech by award-winning Actor and Social Entrepreneur, Jeffery C. Wright, who spoke passionately and intimately about the devastation of the Ebola epidemic on healthcare services in Africa and, recalling Albert Einstein’s definition of insanity, doing the same thing over and over again and expecting different results, he called for a new approach borrowing from the model used in the Marshall Plan, which worked in Europe after the second world war.

The meeting was addressed by Mr. Tarek Ben Youssef, Senior Political Officer in the African Union Mission as host who represented the AU permanent representative Amina Salum Ali, who was delayed returning from the African Union Summit in Addis Abeba.

The 5 panelists who followed Mr. Jeffrey Wright were Mr. Robert Mallet (President Accordia Global Health Foundation), Ms. Jessica Rookwood (President of International Health Advisors), Mr. Donald Shriber (Deputy Director for Policy and Communication, Centers for Disease Control and Prevention), Dr. Pernessa Seele (Founder and CEO, The Balm in Gilead, Inc) and Mr. Gregory Simpkins (Senior Director, US House of Representatives, Sub-committee on Africa).

Five people responding to the panel were Ms. Julia Royall (Global Health Information Specialist), Dr. Gloria B. Herndon (CEO GB Herndon & Associates), Dr. Julius Garvey (Garvey vascular Specialists), Dr. Arikana Chihombori (Chair, African Diaspora Health Initiative, African Union) and Mr. Raymond C. Dabney (Chairman Board of Directors, Cannabis Science Inc., and the Cannabis Science Research Foundation).

The Africa Healthcare Infrastructure Forum & Brainstorm Session, coming on the heels of the 24th meeting of the African Union and the unprecedented international response to the Ebola epidemic, is poised to play a unique and catalytic role to radically transform the global health agenda of Africa from one that lurches from one crisis response to another crisis response to one that is built on health system strengthening, engagement of African communities and professionals, and long-term training and infrastructure investment.

Cannabis Science and the Cannabis Science Research Foundation, through its Chairman Raymond C. Dabney, is pleased to be associated with this historic session, and with the work of CFA, and to join the African Union and partner institutions to re-shape the debate and implementation healthcare reform and investment in Africa. Agreeing with keynote speaker, Jeffrey C. Wright, that the responsibility of healthcare lies with local governments in Africa, thus healthcare system strengthening.

Mr. Dabney believes and re-affirmed that Cannabis Science and the Cannabis Science Research Foundation would respond with urgency and seriousness of purpose, the Africa to support long-term efforts to rebuild Africa’s healthcare infrastructure along the priorities established by the Africa Healthcare Infrastructure Committee. This work will include education and training to replace workers lost in epidemics such as the HIV/AIDS and the Ebola epidemics, revitalization of agriculture, and leadership training. The legacy of the Ebola epidemic in Guinea, Sierra Leone and Liberia should not be a Cassandra Curse, but a vibrant partnership to do what is possible so Africans can manage and deliver health to their own peoples – in other words build the wealth of Africans by supporting the health of its peoples.

“A healthy and vibrant Africa is good for everybody. Imagine the potential of untapped resources of Africa making their fair share contribution to the global economy, including in agricultural production, drug manufacturing and distribution. It is a big market; it is a big supplier. I am personally honored to have been invited to serve on the CFA Africa Healthcare Infrastructure Committee,” said Raymond C. Dabney.  “We have begun the process of bringing influential private and public stakeholders together, as was clearly evident at the historic session at the AU mission, to identify and begin closing the gaps in Africa’s infrastructure and health systems.”

Mr. Dabney was impressed by all the attendees and presenters he spoke with, they were all clearly eager to turn the page, break the cycle of crisis management to long-term solutions. One good example of a long-term solution is the creation of the African Centers for Disease Control and Prevention, described by Mr. Tarek Ben Youssef, to train and equip African front line workers to detect, respond and stop epidemics in their tracks. Another is the establishment, supporting and sustaining African health centers of excellence, such as the Infectious Diseases Institute in Uganda, described by Mr. Mallet. “Clearly a lot is possible and there is no need to re-invent the wheel,” said Mr. Dabney. “But it will take will, focus, determination, and a willingness to engage Africans, but it is possible.”

Goals of the CFA African Healthcare Infrastructure Committee
Following a very positive response to the committee’s initial activity of the Africa Healthcare Infrastructure Forum & Brainstorm Session at the AU Mission, committee plans a fact-finding trip to Africa to visit successful models, such as the Infectious Diseases Institute, the African Field Epidemiology Network – AFENET model (http://afenet.net/), and regional organizations such as the East African Community to discuss initiatives and partnerships with African government and business leaders.

The African Site Visit will be headed by the Mr. Dabney in his capacity as Vice-Chair of the African Healthcare Infrastructure Committee and Mr. Melvin Foote to explore opportunities to develop projects and deploy boots on the ground for projects discussed. The immediate projects will focus on identifying areas of immediate collaboration with the consortium of businesses already engaged to support education and training, food security through agriculture and sanitation, technology and telecommunication, leadership and policy training, and specific health infrastructure issues. The imperative of initial partnerships will be to create jobs and build skills to support the African Health care infrastructure initiatives.  “This imitative makes sense for Cannabis Science, which clearly would like to understand more about the potential of growth the company in Africa,” said Mr. Dabney.

Cannabis Science is seeking new regions to develop business for low-cost cannabis-based therapeutics, which could also meet the acute shortage of pain medications along with many other critical ailment treatments in Africa.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
Tel: 1.888.889.0888

RELATED LINKS

http://www.cfa-network.orghttp://www.cannabisscience.com

0 1647

Cannabis Science President & CEO, Raymond C. Dabney is named Vice Chair of the CFA Africa Healthcare Infrastructure Initiative Committee

COLORADO SPRINGS, Colo., Feb. 9, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, today announced the appointment of Cannabis Science President & CEO, Raymond C. Dabney as Vice Chair of the newly launched Constituency for Africa (CFA) Africa Healthcare Infrastructure Committee. ( www.cfa-network.org ) (https://www.facebook.com/pages/Constituency-for-Africa/347822291974589 )

Mr. Dabney joins Dr. Roscoe M. Moore Jr. (retired US Assistant Surgeon General) who is Interim Chair of CFA and also Chair of the Africa Healthcare Infrastructure Committee, along with 13 others consisting of individuals with extensive experience working in or with Africa in the public and private sectors. Among them is Dr. Julius Garvey, an accomplished board certified surgeon specializing in the diagnosis and treatment of cardiovascular disease, the son of the accomplished Marcus Garvey Jr., and also a pan-Africanist, and Prof. Allen Herman, an independent public health consultant who was the founding Dean of the National School of Public Health, Medical School of Southern Africa in South Africa.

The committee held its inaugural meeting on February 5, 2015 at the African Union Mission to discuss its charge from CFA President, Mr. Melvin Foote, and to approve a minimum program of work. Building on the successful model by CFA of using Town Hall formats and commissioning lectures to highlight priorities, The Committee approved a plan to hold the Africa Healthcare Infrastructure Forum & Brainstorm Session on February 6 at the African Union Mission and to establish five standing subcommittees on EDUCATION, AGRICULTURE, FOOD SECURITY, TECHNOLOGY & COMMUNICATION, LEADERSHIP, POLITICAL ENGAGEMENT & POLICY, and HEALTHCARE INFRASTRUCTURE to develop and sustain programs in these areas.

The Africa Healthcare Infrastructure Forum & Brainstorm Session was held on February 6, 2015 at the African Union Mission in a historic event graced by a Keynote speech by award-winning Actor and Social Entrepreneur, Jeffery C. Wright, who spoke passionately and intimately about the devastation of the Ebola epidemic on healthcare services in Africa and, recalling Albert Einstein’s definition of insanity, doing the same thing over and over again and expecting different results, he called for a new approach borrowing from the model used in the Marshall Plan, which worked in Europe after the second world war.

The meeting was addressed by Ambassador Salum Amina Ali (Ambassador AU Mission) as host, 5 panelists, including Mr. Robert Mallet (President Accordia Global Health Foundation), Ms. Jessica Rookwood (President of International Health Advisors), Mr. Donald Shriber (Deputy Director for Policy and Communication, Centers for Disease Control and Prevention), Dr. Pernessa Seele (Founder and CEO, The Balm in Gilead, Inc) and Mr. Gregory Simpkins (Senior Director, US House of Representatives, Sub-committee on Africa), and 5 respondents, including Ms. Julia Royall (Global Health Information Specialist), Dr. Gloria B. Herndon (CEO GB Herndon & Associates), Dr. Julius Garvey (Garvey vascular Specialists), Dr. Arikana Chihombori (Chair, African Disorders Health Initiative, African Union) and Mr. Raymond C. Dabney (Chairman Board of Directors, Cannabis Science Inc., and the Cannabis Science  Research Foundation).

The Africa Healthcare Infrastructure Forum & Brainstorm Session, coming on the heels of the 24th meeting of the African Union and the unprecedented international response to the Ebola epidemic, is poised to play a unique and catalytic role to radically transform the global health agenda of Africa from one that lurches from one crisis response to another crisis response to one that is built on health system strengthening, engagement of African communities and professionals, and long-term training and infrastructure investment.

Cannabis Science and the Cannabis Science Research Foundation, through its ChairmanRaymond C. Dabney, is pleased to be associated with this historic session, and with the work of CFA, and to join the African Union and partner institutions to re-shape the debate and implementation healthcare reform and investment in Africa. Agreeing with keynote speaker, Jeffrey C. Wright, that the responsibility of healthcare lies with local governments in Africa, thus healthcare system strengthening. Mr. Dabney believes and re-affirmed that Cannabis Science and theCannabis Science Research Foundation would respond with urgency and seriousness of purpose, the Africa to support long-term efforts to rebuild Africa’s healthcare infrastructure along the priorities established by the Africa Healthcare Infrastructure Committee. This work will include education and training to replace workers lost in epidemics such as the HIV/AIDS and the Ebola epidemics, revitalization of agriculture, and leadership training. The legacy of the Ebola epidemic in Guinea, Sierra Leone and Liberia should not be a Cassandra Curse, but a vibrant partnership to do what is possible so Africans can manage and deliver health to their own peoples – in other words build the wealth of Africans by supporting the health of its peoples.

“A healthy and vibrant Africa is good for everybody. Imagine the potential of untapped resources of Africa making their fair share contribution to the global economy, including in agricultural production, drug manufacturing and distribution. It is a big market; it is a big supplier. I am personally honored to have been invited to serve on the CFA Africa Healthcare Infrastructure Committee,” said Raymond C. Dabney.  “We have begun the process of bringing influential private and public stakeholders together, as was clearly evident at the historic session at the AU mission, to identify and begin closing the gaps in Africa’s infrastructure and health systems.”  Mr. Dabney was impressed by all the attendees and presenters he spoke to who were clearly eager to turn the page, break the cycle of crisis management to long term solutions. One good example of a long-term solution is the creation of the African Centers for Disease Control and Prevention, described by Ambassador Salum Amina Ali, to train and equip African front line workers to detect, respond and stop epidemics in their tracks. Another is the establishment, supporting and sustaining African health centers of excellence, such as the Infectious Diseases Institute in Uganda, described by Mr. Mallet.. “Clearly a lot is possible and there is no need to re-invent the wheel” said Mr. Dabney. “But it will take will, focus, determination, and a willingness to engage Africans, but it is possible.”

Goals of the CFA African Healthcare Infrastructure Committee
Following a very positive response to the committee’s initial activity of the Africa Healthcare Infrastructure Forum & Brainstorm Session at the AU Mission, committee plans a fact-finding trip to Africa to visit successful models, such as the Infectious Diseases Institute, the African Field Epidemiology Network – AFENET model (http://afenet.net/), and regional organizations such as the East African Community to discuss initiatives and partnerships with African government and business leaders.  The African Site Visit will be headed by the Mr. Dabney in his capacity as Vice-Chair of the African Healthcare Infrastructure Committee and Mr. Melvin Foote to explore opportunities to develop projects and deploy boots on the ground for projects discussed. The immediate projects will focus on identifying areas of immediate collaboration with the consortium of businesses already engaged to support education and training, food security through agriculture and sanitation, technology and telecommunication, leadership and policy training, and specific health infrastructure issues. The imperative of initial partnerships will be to create jobs and build skills to support the African Health care  infrastructure initiatives.  “This imitative makes sense for Cannabis Science, which clearly would like to understand more about the potential of growth the company in Africa”, said Mr. Dabney. Cannabis Science is seeking new regions to develop business for low-cost cannabis-based therapeutics, which could also meet the acute shortage of pain medications along with many other critical ailment treatments in Africa.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc
Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
Tel: 1.888.889.0888

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-science-president–ceo-raymond-c-dabney-is-named-vice-chair-of-the-cfa-africa-healthcare-infrastructure-initiative-committee-300032779.html

0 1274

Cannabis Science (CBIS) Provides Guidance on the Company’s New Year and Products, Developments and ‘Initiatives in Action’ for 2015

COLORADO SPRINGS, Colo., Feb. 2, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, today announced several updates and significant progress on product commercialization and key developments domestically and internationally from the Americas to Africa to Hong Kong, a key door to Asia.

Highlights
“Overall, the medical cannabis industry is booming and it doesn’t show any signs of slowing down,” said Raymond C. Dabney, the company’s Director, President & CEO and Co-Founder. “In the next two years, a number of states are expected to consider the legalization of both recreational and medical cannabis.  While recreational use is not a part of our business model, we do believe its public and legislative support is one of the key litmus tests for acceptance of medical cannabis.”  Please see sector growth charts from January 29, 2015 in the Huffington Post.

Dabney said Cannabis Science made great strides in 2014, establishing partnerships and joint ventures with partners around the world.  He added that the company is ready to move to the next level in 2015 in terms of expansion of public awareness, commercialization of products, and expansion of capacity to address serious health issues in the U.S. and internationally.  This includes the Company’s African initiative.  Also, not previously announced, Dabney and key team members recently returned from Hong Kong, where promising relationships were formed for the Company’s many initiatives in Asia.

“One of the final steps in taking operations in 2015 to the next level is putting in place a strong media program,” said Dabney. “We are proud to announce we have just retained top media experts to drive media interest in the Company and also in the Foundation.”  Forward looking media coverage will assist the Company’s team in sharing and expanding on its core mission: to develop, produce, and commercialize truly novel therapeutic approaches for the treatment of critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders for patients in need.  “And Cannabis Science’s team is stronger that ever, enhanced by its collaboration with leading experts in drug development, medicinal characterization and clinical research,” noted Dabney. Please see Cannabis Science’s expanding Scientific Advisory Board.

New retail locations in two European countries as well as California
Cannabis Science is making final preparations to bring its products to market and has finalized preliminary retail locations in Spain and the Netherlands, and sites in California.  With these successes, the Company expects an increase in demand in these jurisdictions, others that the Company has announced, and more being actively targeted.

These cannabis and cannabinoid-based products are currently ready for pre-clinical studies, self-medicating patient usage, and marketing release, sales and distribution. The Company is also developing processes to efficiently produce, distribute and market products along with the proper procurement of opt-in, informed consent data collection regarding patient outcomes.  This will establish Cannabis Science with a vertically integrated product pipeline to accommodate varied established and emerging international markets.

The Cannabis Science product launch will begin in the Netherlands and Spain within the next week, and in California the following week.

A strong new partnership in Michigan
In the United States, Cannabis Science is leading the market in Michigan through its subsidiary, Michigan Green Technologies, LLC (MGT), which is recognized as the foremost resource for Michigan legislative initiatives and management consulting in respect of cannabinoid-based drug development, nutraceuticals, cosmeceuticals, and food supplements.  Following a slight administrative delay, MGT is now poised to lead Michigan into a much larger and more successful version of the experience witnessed in Colorado.

Success in California
Cannabis Science also successfully renegotiated its agreement with Apothecary Genetics Investments LLC to purchase and license two northern California production farms with a combined total of 51 acres. The purchase includes all related equipment for cannabis cultivation and production for the state’s substantial medical cannabis market.  The Company is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.

“The overall goal of Cannabis Science in the United States is to offer products as soon as it is legally possible in each state,” said Dabney. “We know the medical need is there, and that means the market is poised and waiting for Cannabis Science in California and beyond.”

Research around the world
In Spain and the Netherlands, Cannabis Science is working closely with the Mediwiet Foundation to conduct an observational study with patients who are self-treating with medicinal cannabis. Cannabis Science also began pre-clinical studies on its CBN patent in Italy and is collaborating with Unistraw in an exciting effort to produce proprietary formulations delivering a wide array of unique cannabis extracts and pure cannabinoid-based products.

The Company is also negotiating with groups in South American countries, such as Uruguay and Colombia, and is exploring similar opportunities in Mexico. All of these countries are part of the Company’s fundamental plan to create a network for efficient licensing and distribution for medical cannabis formulations and products.  The Company intends to add East Asia and Australasia to this network and will make further announcements as developments warrant.

Continued development of an African initiative
Through foundations like the Constituency for Africa, Cannabis Science is also developing political strategies for low-cost cannabis-based therapeutics to address the lack of access to pain medications and other needed treatments in Africa.  This initiative has both philanthropic and commercial elements.

Cannabis Science had recently launched the Patient Access Centre and the Cannabis Science Research Foundation, among other things, to bring the public together to increase public awareness and generate humanitarian contributions to help patients in need.

Join the PAC (Patient Access Centre)

See the Cannabis Science Research Foundation Website

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc
Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
Tel: 1.888.889.0888

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-provides-guidance-on-the-companys-new-year-and-products-developments-and-initiatives-in-action-for-2015-300029053.html

1 1520

Cannabis Science (CBIS) Issues Upbeat Report on its Subsidiary, Michigan Green Technologies (MGT), as Historic Michigan Milestone is Reached with New Hemp Legislation

COLORADO SPRINGS, Colo., Jan. 29, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to issue an update regarding its subsidiary, Michigan Green Technologies LLC (MGT), and the positive evolution of the Michigan legal landscape.

Cannabis Science shares the mission of Michigan Green Technologies in bringing cannabis-based wellness solutions to the people of Michigan. MGT is recognized as the leading resource for Michigan legislative initiatives and management consulting in respect of cannabinoid-based drug development, nutraceuticals, food supplements, cosmeceuticals and food products.

“Michigan leaped forward with the passage into law of the state’s hemp bills.  Cannabis Science is pleased with the strong, professional work of its Michigan-based operations and that of its many Michigan partners.  MGT represents an incredible assemblage of highly qualified individuals — and the team continues to expand.  We look forward to more legislative progress in Michigan over the next few quarters, as Michigan’s and MGT’s business models mature in a parallel fashion,” stated Robert Kane, Director & CFO, Cannabis Science Inc.

MGT celebrated this month’s milestone victory:  the passage of Michigan’s hemp bills. House Bills 5439 and 5440 were put into immediate effect and became Public Act 547.  As the state’s legislative environment continues to mature, the prospects grow for MGT’s successful development and delivery of quality cannabis-based care to patients in need.  Michigan’s progressive, common sense approach to legislation is likely to make it a leading US state in which cannabis-based care is fully integrated into the general healthcare system, thus providing patients with effective products in a safe and regulated manner.

Other updates include the following:

  • MGT continues development in preparation for projects with various of Michigan’s universities to engage and invest in clinical research and educational programs;
  • MGT progresses in securing a potent and talented advisory board that encompasses professionals and experts in law, medicine, law enforcement, state and federal government, and R & D;
  • MGT has created a network of county governmental leaders throughout the state for the purpose of implementation of a statewide pilot program spanning all aspects of a robust hemp program, including education of key stakeholders;
  • MGT is excited about the future of upcoming initiatives, such as the Michigan Medical Marihuana Act and related pending legislation, to rationalize and organize the state’s cannabis program for safe, viable and effective patient care.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc
Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Robert Kane,
Director & CFO
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-issues-upbeat-report-on-its-subsidiary-michigan-green-technologies-mgt-as-historic-michigan-milestone-is-reached-with-new-hemp-legislation-300027887.html

7 8206
marijuana stocks

After a wild year for marijuana stocks in 2014,

many of our viewers and members contacted us asking for our opinion and outlook for 2015. So what did we do? The MarijuanaStocks.com team sought out the advice of an experienced, professional hedge fund trader to see how he was maneuvering this market. The following is his report. Enjoy. We sure did.

Trade and Run or Buy and Hold?

Marijuana Plant or Biotech?

Many people have asked me what the best way to invest in the marijuana industry is. My response is not one specific company but rather an overall strategy based on different niche sectors that has allowed me to profit quite handsomely from a market overflowing with uncertainty, regulation and volatility. Understanding how each niche sector is effected by the evolving industry and how investors react regarding the different risk factors of each sector is key.

I compare the Marijuana Industry to the Internet Boom. The similarities from an investment stand point are eerily similar. Although the Internet was not bound by regulation, the volatility and investor craze was unlike anything I’ve ever seen in my career. But you could NOT just simply put your money into any new Internet company and not check it for a year or two. Maybe 90% of the Internet IPOs failed. But that doesn’t mean there wasn’t massive amounts of money to be made trading them. Then, as the industry developed, matured and the potential of the Internet was fully understood by investors, the Apples, Microsofts, and Yahoos began to separate themselves from the rest of the pack. And those were the companies that you could put your money in and not look at it for years to come.

But when an industry is just starting, as the marijuana sector literally is before our eyes, it is nearly impossible to identify the future leaders when there is so much speculation and outside factors like regulatory issues state by state and by the overall government. That is why I am not holding one single “marijuana company” yet. I am trading them. Why? Because any company that is directly affected by regulation of the cannabis plant is not a safe long-term investment, yet. And I stress the word yet because eventually the industry will mature enough to where a select few marijuana companies will be a buy and hold. But for now, trade the volatility. Get in and get out. During the last 8 months, I am averaging 2-3 day holding periods on cannabis stocks.

Now, there is, however, another niche sector of the cannabis revolution that has been a buy and hold. And that is because it is in no way affected by the regulation of the actual marijuana plant. That sector is biotech. Companies using cannabinoid structures to produce various drugs and medicines to treat specific ailments and hopefully achieve FDA approval. To date, this is the only sector of the cannabis revolution, in my opinion, that has been a safe long term investment.

Volatility levels are nowhere near like what we see in marijuana companies. And that is because the success of a biotech company’s stock is much more determined by the company’s ability to execute on their business plan. A marijuana company can execute their business plan quickly and efficiently and receive proper licensing but will still see negative performance if a major regulatory event hinders the industry. Similar to the overall sell-off we saw in marijuana companies when Florida declined the use of medical marijuana. This is why you must trade these companies quickly. There are too many outside factors that will affect your investment.

Biotech vs. Marijuana

When looking at biotech companies operating in the cannabis space, you see a very steady and solid long term uptrend. On the other hand, when looking at marijuana companies dealing with the plant or ancillary products, you see a distinct long term downtrend with several quick momentum building trades mixed in between. Here are a few examples of what I’m talking about:

Biotech

There are two clear leaders in the cannabis revolution and they are both biotech companies. Neither company actually touches the marijuana plant itself and are not held to the same restrictions and regulatory exposure. This has allowed these two companies to execute on their business plans free of outside risk and uncontrollable factors making them safe long term investments to this point. In addition, the biotech sector is the only niche cannabis sector to see institutional support giving the retail investor a sense of security. Now, of course every stock will have its ups and downs, but the point to take from this is that the biotech sector is the only sector of the marijuana revolution still holding significant gains over the past 12 months or longer.

GW Pharmaceuticals (GWPH)

gwph marijuana stock

INSYS Therapeutics Inc. (INSY)

insy

GWPH and INSY are both sporting solid, consistent uptrends while posting gains well over 500% for those who bought and held over the last 12-24 months. The biotech cannabis sector has proven to be the only niche sector to maintain a long term uptrend making it the only sector, to date, worth holding.

Marijuana

Companies dealing directly with the marijuana plant and/or its ancillary products, have been extremely volatile providing excellent trade opportunities. However, anyone who used the buy and hold model in this sector is left with near worthless investments. This is a direct result of the unknown risk element involved with regulatory actions and investors trying to understand how the state by state approval/denial of medical/recreational marijuana will effect a company’s business model.

Medbox Inc. (MDBX)

mdbx

Medbox would be placed in the ancillary products niche sector. As you can see, MDBX has experienced a severe downtrend over the last 12 months. However, there have been several very profitable quick trades throughout 2014. Take your profits and move on. Anyone who left their money in MDBX for an extended period of time saw their investment melt away.

Medical Marijuana, Inc. (MJNA)

mjna

Medical Marijuana, Inc. has experienced a distinct downtrend for the past 12 months with a couple profitable trades mixed in between. Throughout the entire year, there was only one instance where it was safe to hold MJNA for longer than 4 days.

Cannabis Science Inc. (CBIS)

cbis

Cannabis Science, too, has been in an overall downtrend for the past 12 months with a few profitable trades throughout.

The list of marijuana companies in a downtrend goes on and on with many charts depicting a very similar picture as the ones above. This even stretches into the vapor industry, another ancillary marijuana sector.

Summary

The marijuana industry is growing, but is still in its infancy stage. Similar to what we saw during the Internet Boom, as time progresses I expect to see companies separate themselves from the pack while others fade away into oblivion. Until the outside, uncontrollable risk factors are not as much of a catalyst, marijuana companies will remain nothing more than quick trades for me. But I stress, I am very positive on the future of this industry. I simply think it is still young. As the sector develops, the opportunity for long term buy and hold investments will become clearer.

But as of today, my buy and hold strategy will be in the biotech cannabis space as they are not subject to the regulatory exposure that has proven detrimental to a company’s stock. I will continue to trade the momentum and volatility of marijuana companies because they do provide excellent liquidity and profitable opportunities. But I will likely not hold a position longer than 4-5 days at a time.

1 1617

Cannabis Science, Inc. (CBIS) Gets Set to Release its 8 Initial Cannabis-Based Products Produced and Distributed in California, Spain, and the Netherlands for Self-Medicating Patient Usage for Critical Ailments and Pre-Clinical Studies

COLORADO SPRINGS, Colo., Jan. 16, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announced on January 5th the International release of eight initial products to be produced, distributed and marketed across the Netherlands, Spain and California, where Cannabis Science is active and has cannabis production facilities through ownership and usage agreements.

The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The roll-out will involve Cannabis Science teams in both Europe and California to work in tandem to share information, send formulations to be produced in each respective production facility and share opt-in patient data based on usage metrics to scale demand, while collecting insightful information in each geographical market appropriately.

View photo

.

Preliminary packaging is now being secured and designs are completed for each jurisdiction. Please visit the beta version of the Cannabis Science Pati...

  • Preliminary packaging is now being secured and designs are completed for each jurisdiction. Please visit the beta version of the Cannabis Science Patient Access Center (PAC)http://pac.cannabisscience.com for product release information, patient usage tracking, share your usage and support stories with others worldwide, and valuable industry updates.

Cannabis Science will be announcing shortly where products are available for purchase in each jurisdiction; initial cannabis formulations will be focused on:

  • Topical formulations for cancers
  • Ingestible formulations for cancers, HIV/AIDS and other indications
  • Varied formulations for neurological disorders and other indications depending on delivery methodology required
  • Ingestible and topical formulations for chemotherapy side effects, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, rheumatism, arthritis, infections, diabetes, manic depression, fibromyalgia and other issues
  • Topical formulations for rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain, radiotherapy wounds, rheumatism, open wounds and sensitive and irritated skin, various skin complaints, and wounds

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Photo – http://photos.prnewswire.com/prnh/20150116/169652

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-science-inc-cbis-gets-set-to-release-its-8-initial-cannabis-based-products-produced-and-distributed-in-california-spain-and-the-netherlands-for-self-medicating-patient-usage-for-critical-ailments-and-pre-clinical-st-300021763.html

1 1292

Cannabis Science, Inc. (CBIS) to Release 8 Initial Cannabis-Based Products, Synergistically Produced, Distributed and Marketed Across California, Spain, and the Netherlands, For Pre-Clinical Studies and Immediate Self-Medicating Patient Usage for Critical Ailments

COLORADO SPRINGS, Colo., Jan. 5, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities.

The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The roll-out will involve Cannabis Science teams in both Europe and California to work in tandem to share information, send formulations to be produced in each respective production facility and share patient indicators based on usage metrics to scale demand, while collecting insightful data in each geographical market appropriately. Different logistical capabilities will be developed through internal management to adequately produce, distribute and market products along with the proper procurement of opt-in, informed consent patient data from outcomes to establish Cannabis Science with a vertically integrated product pipeline to accommodate international markets.

Cannabis Science will be announcing shortly where products are available for purchase in each jurisdiction; initial cannabis formulations will be focused on:

  • Topical formulations for cancers
  • Ingestible formulations for cancers, HIV/AIDS and other indications
  • Varied formulations for neurological disorders and other indications depending on delivery methodology required
  • Ingestible and topical formulations for chemotherapy side effects, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, rheumatism, arthritis, infections, diabetes, manic depression, fibromyalgia and other issues
  • Topical formulations for rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain, radiotherapy wounds, rheumatism, open wounds and sensitive and irritated skin, various skin complaints, and wounds

The Cannabis Science Patient Access Center (PAC) http://pac.cannabisscience.com, released in beta version, is now available for patients to track usage and receive updates.

“With the proper distribution channels in place to reach large ranges of patients in different prognosis situations, we intend on releasing our cannabis formulations with specific support channels and applications to provide consumers adequate insight into product specifications, usage recommendations and the opt-in ability to input a variety of sentiments across medical indicators for the appropriate monitoring of effects. Our Scientific Advisory Board and management team is working towards the development of a vertically integrated model to standardize aforementioned practices for multiple other jurisdictions and regulatory environments to accommodate the growth of the sector,” stated Mr. Raymond C. Dabney, Director, President & CEO, Co-Founder, Cannabis Science, Inc.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

Chad S. Johnson, Esq., Director, COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cannabis-science-inc-cbis-to-release-8-initial-cannabis-based-products-synergistically-produced-distributed-and-marketed-across-california-spain-and-the-netherlands-for-pre-clinical-studies-and-immediate-self-medicating-p-300015686.html

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements